An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk.1 This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal. Metamucil and Dr. Michael Roizen, Chairman of the Wellness Institute at Cleveland Clinic and host of the upcoming PBS series, “Younger You,” have joined to present the “Five Things Every American Needs to Do to Lower Their Cholesterol” to encourage Americans to lead a proactive lifestyle with small modifications and dietary changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/metamucil/48409/
An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk.1 This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal. Metamucil and Dr. Michael Roizen, Chairman of the Wellness Institute at Cleveland Clinic and host of the upcoming PBS series, “Younger You,” have joined to present the “Five Things Every American Needs to Do to Lower Their Cholesterol” to encourage Americans to lead a proactive lifestyle with small modifications and dietary changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/metamucil/48409/
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
